Blog

Biorce has won Best Poster in the Drug Development category at ESMO AI 2026. The ESMO AI & Digital Oncology Congress jury recognized our findings showing how clinical-purpose AI outperforms general-purpose LLMs in drafting oncology protocols.

Drafting clinical trial protocols is a rigorous, time-consuming process that demands strict adherence to regulatory and ethical frameworks. Because general models lack clinical trial architectures, we tested a simple question: could our clinical-purpose AI, Aika, generate more complete protocols from a basic prompt under blinded expert review? Here is what we found:

Our research findings

To ensure an unbiased benchmark, we randomly selected 10 Phase II/III interventional oncology trials from ClinicalTrials.gov and fed the exact same prompt, built from each trial's registry brief summary, into four systems: Aika, Claude Opus 4.8, ChatGPT GPT-5.5, and Gemini 3.6. Three blinded oncology Subject Matter Experts (SMEs) then scored all 40 protocols on a 0-to-5 scale across SPIRIT 2025 items 9–34, yielding the following results:

  • Aika significantly outperformed general-purpose models, achieving 73% overall SPIRIT 2025 compliance compared to 21.5% to 57% for the general-AI assistant.

  • Aika generated the longest, most consistent drafts, whereas general-purpose outputs varied widely and left entire sections unaddressed.

  • Aika scored 4.1–4.3/5 on vital operational items, including confidentiality, retention, adherence, and data management, compared to 0.8–1.7 on average for the other models.

A moment to celebrate at ESMO AI

At ESMO AI, we had inspiring conversations with researchers from academia, pharma, and biotech during our poster presentation. In addition, a second Biorce study was selected and defended in a rapid oral session, marking another major milestone for our team. We are truly thankful to the ESMO AI scientific committee for recognizing our research and highlighting the importance of clinical-specific AI in driving more reliable and efficient clinical trials.

Get the inside track on clinical trial innovation Insights that pharma leaders actually read. No fluff.

Submit

Clinical Trials For All participating partner
AICPA SOC 2 certification

©2026 Biorce | All Rights Reserved

Partners with

Google
NVIDIA

Get the inside track on clinical trial innovation Insights that pharma leaders actually read. No fluff.

Submit

Clinical Trials For All participating partner
AICPA SOC 2 certification

©2026 Biorce | All Rights Reserved

Partners with

Google
NVIDIA

Get the inside track on clinical trial innovation Insights that pharma leaders actually read. No fluff.

Submit

Clinical Trials For All participating partner
AICPA SOC 2 certification

Partners with

©2026 Biorce | All Rights Reserved